BMJ article argues that GOLD criteria lead to signficant misdiagnosis of COPD and overprescription of inhaled therapies

According to the authors of an article published in The BMJ on July 1, 2015, the Global Initiative for Obstructive Lung Disease (GOLD) criteria for COPD diagnosis result in significant overdiagnosis and overprescription of inhalers, especially in older men, and should be modified. Martin Miller of the University of Birmingham and Mark Levy of the . . . Read more

Study finds that discontinuing ICS reduces risk of pneumonia in COPD patients

A study published online in CHEST on June 25, 2015 finds that discontinuing inhaled corticosteroids for COPD patients reduced the risk of pneumonia by 37%, with the greatest reduction in risk associated with stopping inhaled fluticasone. The reduction in risk was not as great after discontinuation of budesonide. The study authors identified over 103,000 COPD . . . Read more

DuoResp Spiromax wins silver Medical Design Excellence Award

Teva Pharmaceutical’s DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014. Teva Global Specialty Medicines President and CEO Rob Koremans commented, “Innovative, patient-focused design is extremely important at a time when . . . Read more